General
Preferred name
CLOFARABINE
Synonyms
Clolar ()
Evoltra ()
Clofarex ()
(2R,3R,4S,5R)-5-(6-amino-2-chloro-9H-purin-9-yl)-4-fluoro-2-(hydroxymethyl)oxolan-3-ol ()
NSC-759857 ()
Clofarabine ()
P&D ID
PD003455
CAS
123318-82-1
Tags
prodrug
natural product
drug
available
Approved by
EMA
FDA
First approval
2004
Drug Status
investigational
approved
Drug indication
Myelodysplastic syndrome
Acute lymphoblastic leukaemia
Max Phase
Phase 4
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION A DNA polymerase (α/δ/ε) inhibitor, DNA and ribonucleoside-diphosphate reductase (RR1) inhibitor. (GtoPdb)
DESCRIPTION inducer of DNA damage (Informer Set)
DESCRIPTION Deoxycytidine kinase (dCK) substrate (Tocriscreen Plus)
DESCRIPTION Selective inhibitor of MEK1/2 (Tocris Bioactive Compound Library)
DESCRIPTION Deoxycytidine kinase (dCK) substrate (Tocriscreen Total)
Cell lines
17
Organisms
1
Compound Sets
26
AdooQ Bioactive Compound Library
A10228
Cayman Chemical Bioactives
14125
CeMM library of unique drugs (CLOUD)
ChEMBL Approved Drugs
CHEMBL1750
ChEMBL Drugs
CHEMBL1750
Concise Guide to Pharmacology 2017/18
6802
Drug Repurposing Hub
DrugBank
DB00631
DrugBank Approved Drugs
DB00631
DrugCentral
691
DrugCentral Approved Drugs
691
DrugMAP
DMCVJ86
DrugMAP Approved Drugs
DMCVJ86
Enamine BioReference Compounds
EU-OPENSCREEN Bioactive Compound Library
EOS101535
Guide to Pharmacology
6802
Informer Set
660288
NCATS Inxight Approved Drugs
762RDY0Y2H
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
ReFrame library
Selleckchem Bioactive Compound Library
Clofarabine
TargetMol Bioactive Compound Library
T0297
Tocris Bioactive Compound Library
2600
Tocriscreen Plus
2600
Tocriscreen Total
External IDs
44
Properties
(calculated by RDKit )
Molecular Weight
303.05
Hydrogen Bond Acceptors
8
Hydrogen Bond Donors
3
Rotatable Bonds
2
Ring Count
3
Aromatic Ring Count
2
cLogP
-0.35
TPSA
119.31
Fraction CSP3
0.5
Chiral centers
4.0
Largest ring
6.0
QED
0.65
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Compound status
FDA
Target Type
Enzymes
MOA
ribonucleoside-diphosphate reductase inhibitor
Substrate
DNA Polymerase Inhibitors
Ribonucleoside-Diphosphate Reductase Inhibitors
Ribonucleotide Reductase inhibitor
Target
DNA
DNA polymerase (alpha/delta/epsilon)
Deoxycytidine kinase
Ribonucleoside-diphosphate reductase RR1
RR
POLA1, POLD1, POLE, RRM1, RRM2, RRM2B
Apoptosis related,Autophagy,DNA/RNA Synthesis,RNR
Pathway
DNA Damage/DNA Repair
Primary Target
Other Kinases
Member status
member
Indication
acute lymphoblastic leukemia (ALL)
Therapeutic Class
Anticancer Agents
Source data